Detection of anti-Leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of american visceral leishmaniasis

Clinical and Vaccine Immunology

Volumn 14, Issue 5, 2007, Pages 569-576

  Lemos, Elenice Moreira ^a   Gomes, Izabelle Teixeira ^b   Carvalho, Sílvio Fernando Guimarães ^c   Rocha, Roberta Dias Rodrigues ^b   Pissinate, Jauber Fornaciari ^a   Martins Filho, Olindo Assis ^b   Dietze, Reynaldo ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIBODY; ANTIPROTOZOAL AGENT; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ARTICLE; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; INFANT; LEISHMANIA CHAGASI; PRIORITY JOURNAL; PROMASTIGOTE; SENSITIVITY AND SPECIFICITY; SEROLOGY; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; ANIMAL; BLOOD; CLINICAL TRIAL; FEMALE; FOLLOW UP; IMMUNOLOGY; LEISHMANIA; MALE; METHODOLOGY; PRESCHOOL CHILD;

AMPHOTERICIN B; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFANT; LEISHMANIA; LEISHMANIASIS, VISCERAL; MALE; TREATMENT OUTCOME;

EID: 34250351871     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00354-06     Document Type: Article

References (21)

1. Anam, K., F. Afrin, D. Banerjee, N. Pramanik, S. K. Guha, R. P. Goswami, S. K. Saha, and N. Ali. 1999. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect. Immun. 67:6663-6669.
2. da Matta, V. L., S. Hoshino-Shimizu, R. Dietze, and C. E. Corbett. 2000. Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis. J. Clin. Lab. Anal. 14:5-12.
3. Desjeux, P. 1996. Leishmaniasis - public health aspects and control. Clin. Dermatol. 14:417-423.
4. Galvão, L. M., R. M. Nunes, J. R. Cancado, Z. Brener, and A. U. Krettli. 1993. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 87:220-223.
5. Greiner, M., D. Pfeiffer, and R. D. Smith. 2000. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev. Vet. Med. 45:23-41.
6. Kumar, R., K. Pai, K. Pathak, and S. Sundar. 2001. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 8:1220-1224.
7. Lainson, R., and J. J. Shaw. 1987. Evolution, classification and geographical distribution, p. 1-120. In W. Peters and R. Killick-Kendric (ed.), The leishmaniases in biology and medicine. Academic Press, London, England.
8. Malafiej, E., and E. Spiewak. 2001. The significance of the level of antibodies in the evaluation of the effects of treatment of toxocariasis. Wiad. Parazytol. 47:805-810.
9. Martins-Filho, O. A., M. E. S. Pereira, J. F. Carvalho, J. R. Cançado, and Z. Brener. 1995. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin. Lab. Diagn. Immunol. 2:569-573.
10. Ministério da Saúde, Brasil. 2003. Manual de vigilância e controle de leishmaniose visceral, secretaria de vigilância em saúde. Ministério da Saúde, Brasília, Brazil.
11. Mitre, E., and T. B. Nutman. 2006. IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. J. Allergy Clin. Immunol. 117:939-945.
12. Passos, S., L. P. Carvalho, G. Orge, S. M. Jeronimo, G. Bezerra, M. Soto, C. Alonso, and E. M. Carvalho. 2005. Recombinant Leishmania antigens for serodiagnosis of visceral leishmaniaiais. Clin. Diagn. Lab. Immunol. 12: 1164-1167.
13. Pearson, R. D., and S. A. de Queiroz. 1996. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22:1-13.
14. Ravindran, R., K. Anam, B. C. Bairagi, B. Saha, N. Pramanik, S. K. Guha, R. P. Goswami, D. Banerjee, and N. Ali. 2004. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect. Immun. 72:863-870.
15. Rocha, R. D. R., C. M. F. Gontijo, S. M. Eló-Santos, A. T. Carvalho, R. Corrêa-Oliveira, M. J. Marques, O. Genaro, W. Mayrink, and O. A. Martins-Filho. 2002. Anti-live Leishmania (Viannia) braziliensis promastigote antibodies, detected by flow cytometry, to identify active infection in American cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 35:551-552.
16. Rocha, R. D. R., C. M. F. Gontijo, S. M. Elói-Santos, A. T. Carvalho, R. Corrêa-Oliveira, T. C. Ferrari, M. J. Marques, O. Genaro, W. Mayrink, and A. O. Martins-Filho. 2006. Clinical value of anti-live Leishmania (Viannia) braziliensis immunoglobulin G subclasses, detected by flow cytometry, for diagnosing active localized cutaneous leishmaniasis. Trop. Med. Int. Health 11:156-166.
17. Santarém, N., A. Tomás, A. Ouaissi, J. Tavares, N. Ferreira, A. Manso, L. Campino, J. M. Correia, and A. Codeiro-da-Silva. 2005. Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunol. Lett. 101:18-23.
18. Sundar, S., K. Kumar, V. P. Singh, and T. M. Mahopatra. 1991. Diagnostic lag period in kala-azar: test for early diagnosis needed. J. Assoc. Physicians India 39:651.
19. Sundar, S., and M. Rai. 2002. Laboratory diagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 9:951-958.
20. Swets, J. A. 1998. Measuring the accuracy of diagnostic systems. Science 240:1285-1293.
21. Tanaka, J., T. Ohkusa, T. Yokoyama, T. Matsuhisa, T. Kawai, H. Hashimoto, T. Tomita, K. Hori, K. Nakajima, T. Matsumoto, and H. Miwa. 2006. Host serological response to Helicobacter pylori after successful eradication: long-term follow-up in patients with cured and persistent infection. Aliment. Pharmacol. Ther. 24:239-248.